- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Positive Safety Profile Reported for Atezolizumab/Axi-Cel Combo in DLBCL
April 29th 2020, 1:45am
A manageable safety profile was observed for the combination of atezolizumab and the anti-CD19 chimeric antigen receptor T-cell therapy, axicabtagene ciloleucel, in patients with refractory diffuse large B-cell lymphoma.
Universal Allogeneic CAR T-Cell Product Demonstrates Efficacy in a Cohort of Adult T-ALL
April 29th 2020, 12:46am
The first-in-clinic universal CAR T-cell therapy TruUCAR GC027 induced promising early response rates and demonstrated a manageable safety profile with no evidence of neurotoxicity events or graft-versus-host disease in adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia.
Adopting Multidisciplinary and Evolving Care Plans Are Essential to Treat Cancer and COVID-19
April 29th 2020, 12:43am
Treating patients with cancer and coronavirus disease 2019 depends upon rapidly changing assessments of the standard of care as well as considerations of comorbidities and life expectancy.
Clinical Factors Predict Deterioration Among Patients With Cancer, COVID-19
April 29th 2020, 12:17am
ECOG performance status, cancer type, and type of prior therapy received can predict risk for clinical worsening or death in patients with cancer who contract the coronavirus disease 2019.
Results of a Combined Modality Screening Approach in Women Without Cancer History
April 28th 2020, 11:10pm
Nickolas Papadopoulos, PhD, professor of oncology and pathology, Johns Hopkins University School of Medicine, discusses the results of a study which evaluated a combined modality screening approach in women without a history of cancer.
Dr. DiBiase on Data With DM-CHOC-PEN/Radiation in Cancers Involving the CNS
April 28th 2020, 11:09pm
Steven J. DiBiase, MD, chair and chief of service for the Julia and Ned Arnold Center for Radiation Oncology, NewYork-Presbyterian Queens, vice chairman and assistant interim professor of radiation oncology, Weill Cornell Medicine, discusses data with 4-demethyl-4 cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) plus radiation in cancers involving the central nervous system (CNS).
Bispecific CD19/CD22 CAR T Cells Active in Pediatric Relapsed ALL
April 28th 2020, 11:04pm
Treatment with CD19/22 chimeric antigen receptor CAR T cells induced a promising response in patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
Novel Innate Immune Activator Boosts PD-1 Inhibition Responses in mTNBC
April 28th 2020, 5:56pm
The addition of the novel innate immune activator, Imprime PGG, to checkpoint inhibition with pembrolizumab showed pronounced clinical benefit in patients with previously treated metastatic triple-negative breast cancer.
Adding Durvalumab/Olaparib to Neoadjuvant Chemo Improves pCR in High-Risk HER2-Negative Breast Cancer
April 28th 2020, 4:01am
The addition of durvalumab (Imfinzi) and olaparib (Lynparza) to neoadjuvant paclitaxel was found to improve pathologic complete response rates compared with paclitaxel alone in patients with high-risk, HER2-negative stage II/III breast cancer.
Poziotinib Shows Mixed Findings in Exon 20-Mutant NSCLC
April 28th 2020, 3:01am
Patients with pretreated non–small cell lung cancer and EGFR exon 20 insertions demonstrated a 68.7% disease control rate while on poziotinib systemic therapy.
Capmatinib Shows Clinical Meaningful Activity and Intracranial Responses in MET Exon 14+ NSCLC
April 28th 2020, 3:00am
Results from the GEOMETRY mono-1 study demonstrated antitumor efficacy of and deep and durable responses with capmatinib in 97 patients with advanced non–small cell lung cancer who harbor MET exon 14 mutations.
Talazoparib Improves QOL, But Not OS in Advanced BRCA1/2+ Breast Cancer
April 28th 2020, 2:25am
Treatment with talazoparib did not demonstrate a statistically significant overall survival benefit in patients with BRCA1/2-mutated metastatic HER2-negative breast cancer.
Atezolizumab Plus Vemurafenib/Cobimetinib Impresses in BRAF V600+ Melanoma
April 28th 2020, 1:41am
Treatment with atezolizumab in combination with vemurafenib and cobimetinib was found to significantly improve progression-free survival and produce durable responses versus vemurafenib and cobimetinib alone in treatment-naïve patients with BRAF V600–mutant advanced melanoma.
Dr. Thirman on the Rationale for Using SNDX-5613 in Acute Leukemias
April 28th 2020, 1:28am
Michael J. Thirman, MD, discusses the clinical rationale for using the investigational agent SNDX-5613 to treat a subtype of acute myeloid leukemia and acute lymphoblastic leukemia.
Dr. Wang-Gillam on Results of a Phase 1 Study With Defactinib in Pancreatic Ductal Adenocarcinoma
April 28th 2020, 1:23am
Andrea Wang-Gillam, MD, PhD, discusses the results of a phase 1 study with defactinib in patients with pancreatic ductal adenocarcinoma.
Continuous Dabrafenib/Trametinib Dosing Improves PFS in BRAF+ Melanoma
April 27th 2020, 11:18pm
Continuous dosing with dabrafenib and trametinib improved progression-free survival compared with intermittent dosing in patients with BRAF mutation–positive advanced melanoma.
Analyses Underscore Extent of Frontline Maintenance Niraparib Benefit in Ovarian Cancer
April 11th 2020, 12:24am
The success of frontline maintenance niraparib in the phase III PRIMA trial extends to meeting biomarker-defined and other secondary endpoints and showing positive patient-reported outcomes.
Addition of Trastuzumab to Chemo Boosts Survival in HER2+ Uterine Serous Carcinoma
April 10th 2020, 10:14pm
The addition of trastuzumab to carboplatin and paclitaxel resulted in a significant survival benefit in women with advanced or recurrent, HER2-positive uterine serous carcinoma, with the greatest benefit observed in those with stage III/IV disease who received the regimen up front.
Dr. O'Malley on Increased Benefit of Rucaparib Maintenance in RAD51C/D-Mutant Ovarian Cancer
April 10th 2020, 9:56pm
David O'Malley, MD, discusses the increased benefit of rucaparib maintenance in patients with ovarian cancer who express RAD51C/D mutations.
Dr. Swisher on the Implications of the VELIA Trial in Ovarian Cancer
April 10th 2020, 9:56pm
Elizabeth M. Swisher, MD, discusses the implications of the phase III VELIA/GOG-3005 trial in ovarian cancer.